A recent study indicates that individuals who discontinue popular GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds far faster than those who halt conventional lifestyle plans.
Research printed in a leading health publication demonstrates that while obese individuals frequently drop a large proportion of their body weight while on the medication, the mass comes back at an average rate of nearly a kilo each month upon discontinuation.
"Individuals purchasing such drugs need to be cognizant of the risk of rapid weight regain when the therapy ends," warns expert Dr. Susan Jebb.
This pace of regain implies a reversion to original weight within about a year and a half.
Analyzing Approaches
The research, which looked at dozens of studies involving over 9,000 of participants, compared the results of these new drugs with other pills.
Researchers emphasize that individuals who shed pounds through lifestyle changes alone typically see a more gradual weight regain—perhaps 100 grams monthly—post-intervention.
The Reason for the Quick Regain
Experts suggest the mode of action of the injections explains the accelerated rebound.
The injections copy a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing GLP-1 concentrations far above than the body's typical production might result in the system to generate a reduced amount of its own natural hormone, and could reduce responsiveness to its actions," said Dr. Adam Collins, a nutrition expert.
"Stopping of this medication leads to appetite is uncontrolled, making overeating much more probable."
A Chronic Disease?
Health authorities suggest the jabs for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
Professionals argue that, given the high risk of relapse, the therapy might need to be long-term.
This view is reinforced by pharmaceutical companies, who state that the results "highlight the long-term character of obesity," akin to managing conditions like high blood pressure.
Patient Accounts
People who have come off the medication report a intense resurgence of hunger.
"It felt as if a trigger that goes on and I was suddenly extremely hungry," recalled one woman.
This challenge is compounded if patients have not adopted lasting dietary or behavioural modifications during therapy.
Significant Use
Survey data show that a significant number of adults in the UK have used these injections in the last 12 months, with demand continuing to grow.
- Use is more common among females compared to males.
- The middle-aged demographic shows the highest usage rates.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Finally, clinicians caution that while these medications are powerful agents for shedding pounds, they are not a magic solution and long-term success relies on ongoing behavioural management.
